News Focus
News Focus
Followers 66
Posts 5997
Boards Moderated 0
Alias Born 09/16/2013

Re: LessIsMore post# 521287

Wednesday, 10/12/2022 2:11:22 PM

Wednesday, October 12, 2022 2:11:22 PM

Post# of 818445
I remember when cancer vaccines were not thought to be viable by BP. So now that the top two most knowledgeable, profitable and capable BPs are changing course, though belatedly, is very good news, imo. I don't think a phase2 melanoma trial will be a threat to DCVax-L given (1) the 12-year international trial data that will likely serve as a barrier of entry, (2) the trial is complete and the tld has been submitted to a journal and (3) manufacturing (and likely flaskwork automation & scalability) is nearing completion all before the melanoma p3 trial even starts.

Just saying... of course, I could be wrong.

I believe it’s quite possible Merck was recently told to “go f*** yourself” by LP

I find this to be hilarious, thanks LOL.

Any and all seasoned and unbiased investors would deduce that Merck and Moderna are teaming as competitors in the space. This is hardly good news.


If we’ve been bamboozled long enough, we tend to reject any evidence of the bamboozle. We’re no longer interested in finding out the truth. The bamboozle has captured us. It’s simply too painful to acknowledge, even to ourselves, that we’ve been taken.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News